Biotech and pharma stocks were smashed with the broader markets Monday as the House rejected an economic bailout plan.

The Nasdaq and Amex biotechnology indices were down 3.3% and 3%, respectively. Biotech staple Genentech ( DNA) shed 6.46%, Amgen ( AMGN) gave up 8.52% and Gilead's ( GILD) shares were off by 12.75%.

Biogen Idec. ( BIIB) shares lost 1.77%, to $48.89.

The Amex pharmaceutical index faired worse than the biotech indices, falling 5.45%, to 282.94. Among those hit the hardest, Sanofi Aventis ( SNY) gave up 8.06% and GlaxoSmithKline ( GSK)fell 6.34%.

A few news items:

The drama drags on for ImClone ( IMCL) investors. The company said Monday that its mystery $70-a-share bidder will either make a firm proposal or withdraw its offer by Wednesday. Thus, investors may have to wait until Wednesday, but should find resolution. Of course, Bristol-Myers Squibb ( BMY), which has a standing hostile tender for $62 a share, is also eager for word.

ImClone shares traded down $1.42, or 2.24%, to $61.96, while Bristol shares were off 97 cents, or 4.7%, at $19.85.

Wuxi PharmaTech ( WX) and Covance ( CVD) said Monday that they'll no longer pursue a joint venture in China and the U.S. Wuxi shares fell $2.11, or 11.8%, to $13.83. The company said it will return to its original plan to build and operate a 323,450-square-foot facility in Suzhou, China, set to open in the second half of 2009.

Covance also said it will revert to its original plan to build a world-class preclinical facility in the region. Covance shares fell $2.09, or 2.27%, to $89.84.

If you liked this article you might like

Stocks Mixed After Working on Railroad

Stocks Mixed After Working on Railroad

Stocks Log a Volatile Win

Stocks Log a Volatile Win

Stocks Get Spooked

Stocks Get Spooked

Dow's Gain: 199.89 as GDP Wows Wall Street

Dow's Gain: 199.89 as GDP Wows Wall Street

Stocks Trip Over Charts; Nasdaq Pummeled

Stocks Trip Over Charts; Nasdaq Pummeled